Hoth Therapeutics Announces Over 65% Participants Demonstrate Meaningful Reductions In Pain, Itching In HT-001 Program; HT-001 Well Toleration, No Treatment Discontinuations Seen

Hoth Therapeutics, Inc. (NASDAQ: HOTH) reported positive interim results from its HT-001 program, achieving the primary efficacy endpoint with over 65% of participants experiencing meaningful reductions in pain and itching. The treatment demonstrated a strong safety profile, as no patients required dose reductions or discontinuations of their EGFR inhibitor therapy. HT-001's well-tolerated nature suggests its potential to improve the quality of life for patients facing dermatologic toxicities associated with cancer treatments.